Modality
mRNA
MOA
KIF18Ai
Target
MALT1
Pathway
Proteasome
Rett
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
~Apr 2021
→ ~Jul 2022
Phase 3
Oct 2022
→ Apr 2030
Phase 3Current
NCT05510553
966 pts·Rett
2022-10→2030-04·Completed
966 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-164.0y awayPh3 Readout· Rett
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Complet…
Catalysts
Ph3 Readout
2030-04-16 · 4.0y away
Rett
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05510553 | Phase 3 | Rett | Completed | 966 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 |